Amprion's Global Push in Early Neurodegenerative Diagnosis

SAN FRANCISCO, CA – April 01, 2026 – A diagnostic technology capable of identifying the biological hallmarks of Parkinson’s disease long before severe symptoms emerge is rapidly expanding its global reach. Amprion, the San Francisco-based firm behind the groundbreaking test, has announced a series of strategic moves, including a key partnership in Australia and expanded research collaborations, signaling a new front in the war against neurodegenerative disorders.

The company's expansion is centered on its highly accurate Seed Amplification Assay (SAA), a technology that provides what was once only possible through autopsy: a definitive look at the underlying pathology of diseases like Parkinson's and Lewy body dementia. By establishing new testing sites and strengthening research alliances, Amprion aims to make this biological certainty accessible to patients and researchers worldwide, potentially transforming diagnosis, drug development, and patient care for millions.

The Science of Certainty: Unpacking Seed Amplification

At the heart of Amprion's strategy is its SAAmplify-ɑSYN test, which operates on the revolutionary principle of seed amplification. Neurodegenerative diseases like Parkinson's are characterized by the misfolding of a protein called alpha-synuclein. These misfolded proteins act as "seeds," causing other healthy proteins to misfold and clump together, forming toxic aggregates that damage the brain.

The SAA technology works by taking a small sample of a patient's cerebrospinal fluid and placing it in an environment with a large supply of healthy alpha-synuclein proteins. If even a minuscule amount of the misfolded "seed" is present, it triggers a rapid, chain-reaction amplification process. This creates a detectable signal, confirming the presence of the disease's core pathology.

This method has demonstrated remarkable, autopsy-confirmed diagnostic accuracy, earning Amprion a Breakthrough Device Designation from the U.S. Food and Drug Administration in 2019. It represents a monumental shift away from diagnoses based on clinical symptoms, which can be ambiguous and often appear only after significant neurological damage has occurred. By providing a clear "yes" or "no" answer based on the disease's biological signature, the test empowers clinicians to make more confident decisions earlier in the disease course.

While the current test is qualitative, research is already underway to develop quantitative versions that could measure the amount of pathological protein, potentially allowing doctors to track disease progression and measure the effectiveness of new treatments in real-time.

A Strategic Global Footprint

Amprion's recent announcements underscore an aggressive global expansion strategy designed to establish its SAA technology as the worldwide standard. A cornerstone of this plan is a new partnership with Macquarie University in Australia, which will create the continent's first-ever clinical alpha-synuclein seed amplification testing site.

“Macquarie University’s leadership in neurodegenerative disease research across Parkinson’s, Alzheimer’s, ALS/MND, and REM Sleep Behavior Disorder makes it a strong partner in advancing this technology,” said Russ Lebovitz, MD, PhD, CEO and co-founder of Amprion, in a statement. “Establishing Australia’s first alpha-synuclein seed amplification testing site is an important step in expanding global access to more precise diagnostic tools.”

This move provides Australian patients and researchers with local access to a technology that was previously difficult to obtain. Beyond Australia, the company is actively pursuing partnerships with major hospital networks across Europe, South Korea, and China. This expansion requires navigating complex international regulatory frameworks, from the European Medicines Agency's In Vitro Diagnostic Regulation (IVDR) to the requirements of South Korea's Ministry of Food and Drug Safety (MFDS) and China's National Medical Products Administration (NMPA).

Bolstering this global push is a fortified intellectual property portfolio. With the recent addition of a patent in China, Amprion now holds protections in all major global markets, securing its leadership position and creating a significant barrier to entry for potential competitors in the SAA space.

Powering a New Era of Research

Beyond its clinical diagnostic utility, SAA technology is proving to be an invaluable tool for accelerating scientific research. Amprion announced it will continue its work with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through 2026 on multiple initiatives, most notably the Parkinson’s Progression Markers Initiative (PPMI).

The SAA test is now an integral part of the inclusion criteria for the PPMI study, one of the most comprehensive investigations into Parkinson's disease ever undertaken. This is a critical development for the field. In the past, clinical trials for Parkinson's therapies have been hampered by the inclusion of participants who, despite showing symptoms, did not have the underlying alpha-synuclein pathology. This can dilute trial results and lead to the failure of potentially effective drugs.

By using the SAA test to screen participants, researchers can ensure their study populations are biologically verified, leading to more reliable data and a higher chance of success. This collaborative effort is also exploring how SAA data can be used to better understand disease progression and to validate the use of the test on different sample types, which could one day lead to less invasive testing methods using blood or skin biopsies.

From Diagnosis to Precision Medicine

The rapid growth in demand for Amprion's test has prompted the company to expand its office space and secure redundant manufacturing for its testing components, ensuring it can support the increasing volume. This scaling is indicative of a broader shift in neurology. An early, accurate diagnosis is no longer seen as the end of the road but as the critical first step toward personalized patient management and the development of precision medicine.

Amprion is already looking ahead, developing biomarker panels that combine its SAA test with other key indicators of neurodegeneration, such as Tau and Amyloid-beta proteins. Such comprehensive panels will provide clinicians with a more complete picture of a patient's pathology, helping to differentiate between complex conditions and guide more targeted therapeutic strategies.

As this technology becomes more accessible across the globe, it offers the promise of fundamentally changing the timeline of neurodegenerative disease. For countless individuals and families, moving from years of diagnostic uncertainty to a clear, biologically-backed answer represents a profound step forward in their journey. This shift empowers patients, refines research, and brings the entire medical community closer to the ultimate goal of finding effective, disease-modifying treatments.